Related Experiment Video
Updated: Jun 13, 2025
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Efficacy and Safety of Botulinum Toxin Type A in Primary Axillary Hyperhidrosis: A Meta-analysis and Systematic
Jing Sun1, Shuangyu Chen2, Ting Yang3
1Department of Dermatology, Pidu District People's Hospital, The Third Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
Background:
The clinical efficacy of botulinum toxin type A (BTX-A) injections for the treatment in primary axillary hyperhidrosis is a subject of ongoing debate. This study aims to consolidate and analyze the available evidence regarding the use of BTX-A as a therapeutic intervention for this conclusion.
Method:
This study was conducted in accordance with PRISMA guidelines and registered with PROSPERO. We included RCTs on BTX-A injections for PAH, comparing it to placebo or other treatments. A comprehensive literature search was conducted in multiple databases up to May 2024. Out of identified articles, some underwent full-text review and were included in the qualitative and quantitative synthesis. Statistical analyses were done using RevMan5.4, and study quality was assessed with the Cochrane risk of bias tool. Subgroup and sensitivity analyses were also conducted.
Result:
Twelve studies met our inclusion criteria (n = 904). BTX-A injection showed greater sweat reduction compared to placebo by gravimetric measurement (116.12 [92.68-139.57]; P < 0.05). BTX-A injection showed comparable sweat reduction to other treatments by gravimetric measurement (26.14 [- 26.8, 79.07]; P = 0.333) and HDSS (- 0.85 [- 1.20, 0.50], P = 0.413). The pain score of BTX-A injection is comparable to other treatments (- 0.41 [- 1.11, 0.29], P = 0.456). BTX-A injection exhibited fewer side effects compared to other treatments (0.18 [0.07, 0.43], P < 0.05).
Conclusion:
In primary axillary hyperhidrosis, BTX-A injection significantly reduces sweat production compared with placebo, and there is no statistically significant difference compared with other treatments. BTX-A injection had less fewer side effects compared with other treatments.
Level Of Evidence I:
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
01:19Depolarizing Blockers: Pharmocokinetics
01:14Assessing Body Temperature - Axilla
Step 1: Perform hand hygiene and put on clean gloves to maintain infection control and prevent cross-contamination.
Step 2: Prepare the patient by explaining the procedure to ensure understanding and cooperation. Ensure privacy, expose the axilla, and inform the patient that minimal movement is crucial for an accurate reading.
Step 3: Adjust the patient’s clothing to expose only the axilla. It minimizes...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:31Skeletal Muscle Relaxants: Therapeutic Uses